TY - JOUR
T1 - Animal models
T2 - Usefulness for studies of fungal pathogenesis and drug efficacy in aspergillosis
AU - Andriole, Vincent T.
AU - Miniter, Peggy
AU - George, David
AU - Kordick, Dorsey
AU - Patterson, Thomas F
PY - 1992/3/1
Y1 - 1992/3/1
N2 - This review describes our experience during the past 8 years with an immunocompromised rabbit model of invasive aspergillosis. We have used the model to evaluate the efficacy of a variety of antifungal therapies, including amphotericin B-deoxycholate, a liposomal amphotericin B preparation, some of the newer azoles (i.e., fluconazole, saperconazole, and the experimental compound SCH 39304), and combination therapy with amphotericin B-deoxycholate plus fluconazole. The model provides a rigorous test of efficacy when animals receive a lethal challenge; permits studies of the kinetics of aspergillar antigenemia in response to therapy with each antifungal agent or regimen; allows comparison of the relation of antigenemia to the extent of disease in target organs; and is useful in correlating the timing of antifungal therapy with the success of treatment. These observations in our animal model may provide some insight into the treatment of invasive aspergillosis in humans.
AB - This review describes our experience during the past 8 years with an immunocompromised rabbit model of invasive aspergillosis. We have used the model to evaluate the efficacy of a variety of antifungal therapies, including amphotericin B-deoxycholate, a liposomal amphotericin B preparation, some of the newer azoles (i.e., fluconazole, saperconazole, and the experimental compound SCH 39304), and combination therapy with amphotericin B-deoxycholate plus fluconazole. The model provides a rigorous test of efficacy when animals receive a lethal challenge; permits studies of the kinetics of aspergillar antigenemia in response to therapy with each antifungal agent or regimen; allows comparison of the relation of antigenemia to the extent of disease in target organs; and is useful in correlating the timing of antifungal therapy with the success of treatment. These observations in our animal model may provide some insight into the treatment of invasive aspergillosis in humans.
UR - http://www.scopus.com/inward/record.url?scp=85047699320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047699320&partnerID=8YFLogxK
U2 - 10.1093/clinids/14.Supplement_1.S134
DO - 10.1093/clinids/14.Supplement_1.S134
M3 - Article
C2 - 1562686
SN - 1058-4838
VL - 14
SP - S134-S138
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
ER -